CSPC Pharmaceutical Group Limited Share Price
Stocks
1093
HK1093012172
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.000 HKD | +5.96% |
|
+19.58% | -5.10% |
| 18/06 | CSPC Pharma's Tumor Drug Gets Trial Nod from US FDA | MT |
| 18/06 | CSPC Pharma Unit's Marketing Application for Anti-Inflammatory Drug Accepted in China | MT |
| Market Cap | 9.15TCr 1.17TCr 1.02TCr 937.33Cr 873.91Cr 1.66TCr 1,11000Cr 1.68TCr 11TCr 4.37TCr 55TCr 4.38TCr 4.28TCr 1,88200Cr | P/E 2026 * |
11.1x | P/E 2027 * | 13x |
|---|---|---|---|---|---|
| Enterprise Value | 8.04TCr 1.03TCr 896.51Cr 824.08Cr 768.33Cr 1.46TCr 98TCr 1.48TCr 9.87TCr 3.85TCr 48TCr 3.85TCr 3.77TCr 1,65500Cr | EV / Sales 2026 * |
2.26x | EV / Sales 2027 * | 2.22x |
| Free-Float |
67.42% | Yield 2026 * |
4.49% | Yield 2027 * | 4.57% |
| 1 day | +5.96% | ||
| 1 week | +19.58% | ||
| Current month | +14.78% | ||
| 1 month | +10.50% | ||
| 3 months | -17.61% | ||
| 6 months | -5.66% | ||
| Current year | -5.10% |
| 1 week | 6.65 |  | 8.08 |
| 1 month | 6.53 | | 8.08 |
| Current year | 6.53 | | 10.96 |
| 1 year | 6.53 | | 11.63 |
| 3 years | 4.27 | | 11.63 |
| 5 years | 4.27 | | 11.9 |
| 10 years | 3.45 | | 13.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lei Cai
CEO | Chief Executive Officer | 46 | 19/12/2025 |
Qing Jie Wei
COO | Chief Operating Officer | 56 | 19/12/2025 |
Zhi Yong Qu
PRN | Corporate Officer/Principal | 44 | 01/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 72 | 26/08/2011 |
Zhen Guo Wang
BRD | Director/Board Member | 56 | 20/01/2012 |
Bo Wang
BRD | Director/Board Member | 66 | 21/12/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 23/06 | Other | Chief Operating Officer | -14,00,000 | 0.0122% | ||
| 23/06 | Other | Director | -7,00,000 | 0.0061% | ||
| 22/06 | Other | Chairman | 1,46,50,000 | 0.1271% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.96% | +19.58% | -1.84% | +14.94% | 1.17TCr | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,08200Cr | |
| +3.57% | +3.29% | +68.60% | +61.03% | 63TCr | |
| +3.99% | +3.05% | +37.93% | +93.37% | 46TCr | |
| -0.26% | +1.37% | +31.00% | +23.97% | 34TCr | |
| -0.56% | +0.96% | +39.86% | +36.64% | 30TCr | |
| -0.08% | +1.30% | +30.37% | +44.02% | 29TCr | |
| -1.54% | +2.81% | -27.56% | -39.45% | 22TCr | |
| +3.55% | +4.41% | +25.45% | +66.28% | 20TCr | |
| +4.21% | +2.65% | +17.47% | +71.11% | 16TCr | |
| Average | +2.07% | +5.97% | +27.68% | +53.50% | 37.04TCr | |
| Weighted average by Cap. | +1.88% | +5.47% | +41.61% | +82.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.56TCr 453.45Cr 396.47Cr 364.44Cr 339.78Cr 643.88Cr 43TCr 654.07Cr 4.37TCr 1.7TCr 21TCr 1.7TCr 1.67TCr 73TCr | 3.51TCr 448.01Cr 391.72Cr 360.07Cr 335.71Cr 636.16Cr 43TCr 646.23Cr 4.31TCr 1.68TCr 21TCr 1.68TCr 1.65TCr 72TCr |
| Net income | 790.33Cr 100.78Cr 88Cr 81Cr 76Cr 143.1Cr 9.59TCr 145.36Cr 970.53Cr 377.91Cr 4.72TCr 378.24Cr 370.09Cr 16TCr | 689.43Cr 88Cr 77Cr 71Cr 66Cr 124.83Cr 8.37TCr 126.8Cr 846.62Cr 329.66Cr 4.11TCr 329.95Cr 322.83Cr 14TCr |
| Net Debt | -1.11TCr -140.91Cr -123.2Cr -113.25Cr -105.59Cr -200.08Cr -13TCr -203.25Cr -1.36TCr -528.4Cr -6.6TCr -528.87Cr -517.47Cr -23TCr | -1.33TCr -170.05Cr -148.68Cr -136.67Cr -127.42Cr -241.46Cr -16TCr -245.28Cr -1.64TCr -637.67Cr -7.96TCr -638.23Cr -624.47Cr -27TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | HK$8.000 | +5.96% | 17,90,55,173 |
| 02/26/02 | HK$7.550 | +8.32% | 17,21,06,946 |
| 30/26/30 | HK$6.970 | -2.52% | 13,18,19,809 |
| 29/26/29 | HK$7.150 | +6.88% | 15,64,40,253 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1093 Stock
Select your edition
All financial news and data tailored to specific country editions
